Viz HCM Showcases New Evidence at ACC Scientific Session
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Should l Buy BMY?
Source: Newsfilter
- Clinical Research Findings: Three studies featuring Viz HCM will be presented at the 2026 American College of Cardiology Annual Scientific Session, highlighting its effectiveness in detecting hypertrophic cardiomyopathy (HCM), which is expected to promote early diagnosis and treatment accessibility, ultimately improving patient outcomes.
- AI Technology Application: Viz HCM is the first FDA-cleared AI algorithm capable of detecting HCM from a standard 12-lead ECG, helping to identify nearly 85% of undiagnosed patients, showcasing its significance and potential in cardiovascular care.
- Impact of Empirical Studies: Research conducted at The Christ Hospital Health Network demonstrated that AI-enabled ECG screening successfully identified 11 new HCM patients, indicating that embedding AI technology within healthcare systems can effectively close diagnostic gaps and enhance ongoing care coordination.
- Future Outlook: The studies suggest that AI-ECG not only facilitates earlier disease detection but also reshapes how health systems monitor and follow patients over time, positioning Viz.ai's technology to play a larger role in cardiovascular care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 58.540
Low
37.00
Averages
55.86
High
68.00
Current: 58.540
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bristol-Myers Squibb Co: Findings Indicate Camzyos Could Be the First Targeted Pharmacological Treatment for OHCM in Adolescents
Research Findings: Bristol-Myers Squibb's results indicate the potential of Camzyos as a first targeted pharmacological therapy for treating OHC in adolescents.
Therapeutic Implications: The study highlights the significance of targeted therapies in addressing specific health conditions in younger populations.
See More
Bristol Myers Squibb Reports Positive Results for Heart Drug Camzyos
- Clinical Trial Results: Bristol Myers Squibb's heart drug Camzyos demonstrated significant efficacy in a Phase 3 trial involving adolescents aged 12 to 17, effectively reducing heart pressure and improving heart function and symptoms, indicating its potential to be the first approved treatment for rare heart disease in this demographic.
- Patient Improvement: Among the 44 patients in the trial, those treated with Camzyos exhibited consistent improvements across various heart performance metrics, including reduced obstruction and changes in heart structure, highlighting the drug's effectiveness and potential market in adolescent patients.
- Safety Assessment: The safety profile of Camzyos was encouraging, with side effect rates similar between the drug and placebo groups, and no new safety concerns identified during the study, further bolstering its prospects for use in younger patients.
- Future Research Plans: Bristol Myers Squibb intends to continue studying Camzyos and present longer-term results in the future; if approved by regulators, the drug could provide a new treatment option for adolescents, potentially improving symptoms and reducing the need for more invasive procedures.
See More
Camzyos Achieves Positive Results in Adolescent Hypertrophic Cardiomyopathy Trial
- Trial Success: Camzyos met its primary endpoint in the SCOUT-HCM Phase 3 trial, demonstrating a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 with a least-squares mean difference of −48.0 mm Hg (P < 0.0001), indicating its potential as a treatment for adolescent hypertrophic cardiomyopathy.
- Safety Profile: The safety profile of Camzyos in adolescents was comparable to that in adults, with no new safety signals identified and no patients experiencing left ventricular ejection fraction (LVEF) below 50%, providing reassurance for its use in this population.
- Multiple Improvements: In addition to the primary endpoint, Camzyos showed significant improvements in several secondary endpoints, including LV obstruction and diastolic function, reinforcing its position as a leading treatment option for adolescents with obstructive hypertrophic cardiomyopathy.
- Future Prospects: Bristol Myers Squibb plans to present 56-week data at an upcoming medical congress, further validating the long-term efficacy and safety of Camzyos, potentially offering a paradigm-changing treatment option for adolescent patients.
See More
Bristol-Myers Squibb Stock Analysis and Outlook
- Mixed Analyst Sentiment: Approximately 60% of analysts maintain neutral ratings on Bristol-Myers Squibb (BMY), despite strong momentum in the healthcare sector, indicating a divergence in market perception that could affect investor confidence.
- Price Target Increase: HSBC raised BMY's price target from $53 to $60, implying a 10% upside, reflecting confidence in the sector's resilience amid geopolitical risks, which may bolster stock performance in the near term.
- Positive Clinical Trial Results: BMY's experimental oral drug mezigdomide showed significant survival improvements in relapsed multiple myeloma patients without increasing disease worsening risk, highlighting its market potential with an estimated 36,000 new U.S. cases projected for 2026.
- Company Development Focus: Bristol-Myers Squibb is dedicated to developing biopharmaceuticals, including small molecules, biologics, and CAR-T therapies, focusing on innovative treatments in oncology, hematology, and other specialty disease areas globally, underscoring its strategic importance in the industry.
See More
Bristol Myers Squibb's Cobenfy Clinical Trial Shows Positive Results
- Clinical Trial Results: Bristol Myers Squibb's Cobenfy demonstrated stability in 105 schizophrenia patients over an 8-week Phase 4 trial, with mean PANSS scores remaining below baseline regardless of cross-titration strategy, indicating its efficacy and safety in treatment.
- High Patient Completion Rate: Approximately 86% of patients completed the 8-week treatment, with discontinuation rates of 15.1% in the slower and 13.5% in the faster transition groups, and no patients discontinued due to lack of efficacy, showcasing Cobenfy's good tolerability.
- Significant Symptom Improvement: The mean change in PANSS total scores was -4.2 for the slower transition group and -3.1 for the faster group, with both groups showing a CGI-S score change of -0.2, indicating notable symptom improvement and supporting Cobenfy's clinical application potential.
- Innovative Treatment Mechanism: As the first novel mechanism for schizophrenia treatment in decades, Cobenfy provides crucial clinical data that aids physicians in making informed decisions during patient treatment transitions, advancing progress in mental health care.
See More
CNBC Investing Club March Meeting Overview
- Energy Stocks Surge: Following the outbreak of war in Iran, energy stocks, particularly fertilizer manufacturers, have shown strong performance, indicating robust market demand that could drive profitability for related companies.
- AWS Growth Acceleration: Amazon's cloud unit AWS is no longer lagging behind Microsoft Azure, thanks to its partnership with Anthropic, with expectations for next quarter's margins to exceed market forecasts, boosting investor confidence.
- Cybersecurity Challenges: CrowdStrike has been affected by turmoil in the software market, but the CEO highlighted the positive impact of AI on cyberattacks, indicating long-term growth potential in the security sector, despite high stock prices.
- Healthcare Sector Risks: Eli Lilly faces pricing pressure from competitor Novo Nordisk, but the company is prepared to counter this by increasing volume, with the upcoming launch of its GLP-1 obesity drug expected to drive growth.
See More
Bristol-Myers Squibb Co: Findings Indicate Camzyos Could Be the First Targeted Pharmacological Treatment for OHCM in Adolescents
Research Findings: Bristol-Myers Squibb's results indicate the potential of Camzyos as a first targeted pharmacological therapy for treating OHC in adolescents.
Therapeutic Implications: The study highlights the significance of targeted therapies in addressing specific health conditions in younger populations.
See More
Bristol Myers Squibb Reports Positive Results for Heart Drug Camzyos
- Clinical Trial Results: Bristol Myers Squibb's heart drug Camzyos demonstrated significant efficacy in a Phase 3 trial involving adolescents aged 12 to 17, effectively reducing heart pressure and improving heart function and symptoms, indicating its potential to be the first approved treatment for rare heart disease in this demographic.
- Patient Improvement: Among the 44 patients in the trial, those treated with Camzyos exhibited consistent improvements across various heart performance metrics, including reduced obstruction and changes in heart structure, highlighting the drug's effectiveness and potential market in adolescent patients.
- Safety Assessment: The safety profile of Camzyos was encouraging, with side effect rates similar between the drug and placebo groups, and no new safety concerns identified during the study, further bolstering its prospects for use in younger patients.
- Future Research Plans: Bristol Myers Squibb intends to continue studying Camzyos and present longer-term results in the future; if approved by regulators, the drug could provide a new treatment option for adolescents, potentially improving symptoms and reducing the need for more invasive procedures.
See More
Camzyos Achieves Positive Results in Adolescent Hypertrophic Cardiomyopathy Trial
- Trial Success: Camzyos met its primary endpoint in the SCOUT-HCM Phase 3 trial, demonstrating a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 with a least-squares mean difference of −48.0 mm Hg (P < 0.0001), indicating its potential as a treatment for adolescent hypertrophic cardiomyopathy.
- Safety Profile: The safety profile of Camzyos in adolescents was comparable to that in adults, with no new safety signals identified and no patients experiencing left ventricular ejection fraction (LVEF) below 50%, providing reassurance for its use in this population.
- Multiple Improvements: In addition to the primary endpoint, Camzyos showed significant improvements in several secondary endpoints, including LV obstruction and diastolic function, reinforcing its position as a leading treatment option for adolescents with obstructive hypertrophic cardiomyopathy.
- Future Prospects: Bristol Myers Squibb plans to present 56-week data at an upcoming medical congress, further validating the long-term efficacy and safety of Camzyos, potentially offering a paradigm-changing treatment option for adolescent patients.
See More
Bristol-Myers Squibb Stock Analysis and Outlook
- Mixed Analyst Sentiment: Approximately 60% of analysts maintain neutral ratings on Bristol-Myers Squibb (BMY), despite strong momentum in the healthcare sector, indicating a divergence in market perception that could affect investor confidence.
- Price Target Increase: HSBC raised BMY's price target from $53 to $60, implying a 10% upside, reflecting confidence in the sector's resilience amid geopolitical risks, which may bolster stock performance in the near term.
- Positive Clinical Trial Results: BMY's experimental oral drug mezigdomide showed significant survival improvements in relapsed multiple myeloma patients without increasing disease worsening risk, highlighting its market potential with an estimated 36,000 new U.S. cases projected for 2026.
- Company Development Focus: Bristol-Myers Squibb is dedicated to developing biopharmaceuticals, including small molecules, biologics, and CAR-T therapies, focusing on innovative treatments in oncology, hematology, and other specialty disease areas globally, underscoring its strategic importance in the industry.
See More
Bristol Myers Squibb's Cobenfy Clinical Trial Shows Positive Results
- Clinical Trial Results: Bristol Myers Squibb's Cobenfy demonstrated stability in 105 schizophrenia patients over an 8-week Phase 4 trial, with mean PANSS scores remaining below baseline regardless of cross-titration strategy, indicating its efficacy and safety in treatment.
- High Patient Completion Rate: Approximately 86% of patients completed the 8-week treatment, with discontinuation rates of 15.1% in the slower and 13.5% in the faster transition groups, and no patients discontinued due to lack of efficacy, showcasing Cobenfy's good tolerability.
- Significant Symptom Improvement: The mean change in PANSS total scores was -4.2 for the slower transition group and -3.1 for the faster group, with both groups showing a CGI-S score change of -0.2, indicating notable symptom improvement and supporting Cobenfy's clinical application potential.
- Innovative Treatment Mechanism: As the first novel mechanism for schizophrenia treatment in decades, Cobenfy provides crucial clinical data that aids physicians in making informed decisions during patient treatment transitions, advancing progress in mental health care.
See More
CNBC Investing Club March Meeting Overview
- Energy Stocks Surge: Following the outbreak of war in Iran, energy stocks, particularly fertilizer manufacturers, have shown strong performance, indicating robust market demand that could drive profitability for related companies.
- AWS Growth Acceleration: Amazon's cloud unit AWS is no longer lagging behind Microsoft Azure, thanks to its partnership with Anthropic, with expectations for next quarter's margins to exceed market forecasts, boosting investor confidence.
- Cybersecurity Challenges: CrowdStrike has been affected by turmoil in the software market, but the CEO highlighted the positive impact of AI on cyberattacks, indicating long-term growth potential in the security sector, despite high stock prices.
- Healthcare Sector Risks: Eli Lilly faces pricing pressure from competitor Novo Nordisk, but the company is prepared to counter this by increasing volume, with the upcoming launch of its GLP-1 obesity drug expected to drive growth.
See More
